Skip to Main Content

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Conditions

Other Urinary | Urinary Bladder

Phase II

What is the purpose of this trial?

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.

Approximately 140 patients are anticipated to be enrolled across approximately 50 sites from North America and Europe.

  • Trial with
    Immunomedics, Inc.
  • Start Date
    06/01/2022
  • End Date
    06/30/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/29/2022
  • Study HIC
    #2000023211